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Kidney disease may be linked to a decline in cognitive
activity. We examined the association of microalbuminuria
and cognitive function in a general population of older adults
in the United States drawn from the National Health and
Nutrition Examination Survey of 1999–2002. Cognitive
function was measured by digit symbol substitution in
2386 participants 60 years of age and older of whom 448
had microalbuminuria. Covariates included age, gender, race/
ethnicity, education, smoking, diabetes, and hypertension.
Among participants with peripheral artery disease, those
with microalbuminuria had a significantly lower
cognitive function score compared to those with a
normal albumin-to-creatinine ratio. The association
between microalbuminuria and cognitive function was
weak in those without peripheral artery disease. But in
those with peripheral artery disease, the odds of
microalbuminuria associated with cognitive function
in the lowest and middle tertiles was 6.5 and 3.5, respectively.
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Decline in cognitive function is a growing public health
problem for the elderly population. Approximately 15% of the
US population over 65 years of age have frank dementia, while
estimates suggest that 30–45% of the elderly population
experience milder forms of cognitive impairment.1–3 Cognitive
impairment is associated with disability, increased home health-
care use, hospitalization, entry into skilled nursing facilities, and
mortality.1,4–6 In addition, persons with cognitive function loss
may experience adverse psychosocial and economic burdens.
There is growing evidence that chronic kidney disease
(CKD) is associated with cognitive impairment in older
adults.7–14 Patients undergoing treatment for end-stage renal
disease are at greater risk for having cognitive impairment than
the general population.8,10,12,15 Furthermore, the presence of
even mild kidney dysfunction (estimated by a glomerular
filtration rate (GFR) of 45–59 ml min1 1.73 m2) indepen-
dently predicts the development of cognitive impairment.7
Albuminuria may be one of the earliest markers of CKD. It
is generally thought to arise as a consequence of glomerular
capillary leak, and likely also represents a marker for systemic
atherosclerosis and endothelial dysfunction.16,17 Yet, there
are currently no studies examining the relationship of
albuminuria with cognitive dysfunction.
We therefore examined the association of microalbumin-
uria and cognitive impairment in a general population
sample of older adults.
RESULTS
The characteristics of the study population are shown
in Table 1. The population had a mean age of 71 years
(range: 60–85 years), was predominantly white (90% white,
7% African American, and 3% Mexican American), and
had slightly more women (56%) than men. Of the 2386
participants included in the study, 18.8% (N¼ 448) had
evidence of microalbuminuria and 81.2% (N¼ 1938) had
normal levels of urinary albumin-to-creatinine ratio concen-
trations. Differences in the distributions of age, education,
alcohol use, diabetes, blood pressure, C-reactive protein,
ankle-brachial index, and peripheral artery disease were
observed between persons with and without microalbumin-
uria (Table 1). Also, participants with microalbuminuria
demonstrated significantly lower mean levels of cognitive
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function than those without microalbuminuria as demon-
strated by the digit symbol substitution (DSS) scores of 41.6
and 49.6, respectively. Due to the statistically significant
interaction of peripheral artery disease with microalbumin-
uria, all further analyses were stratified on the basis of
peripheral artery disease status. This interaction was ordinal,
indicating that the effect estimates for the association between
microalbuminuria and cognitive function were in the same
direction for persons with and without peripheral artery
disease, but were of greater magnitude for the former. There
were 231 persons with peripheral artery disease and 1803
persons without peripheral artery disease in a total of 2034.
The relationship between cognitive function and micro-
albuminuria varied by the presence or absence of peripheral
artery disease. Cognitive functioning based on DSS scores
was higher among persons with peripheral artery disease
(mean DSS score: 41.1±1.1) than those without it (mean
DSS score: 49.9±0.7) (not shown). The prevalence of
microalbuminuria was also higher among persons with
peripheral artery disease (18.7%) compared to those without
it (13.6%). Figure 1 shows the prevalence of microalbumi-
nura by tertile of DSS score and stratified by peripheral artery
disease status. As shown, the percentage of study participants
with microalbuminuria decreased with greater cognitive
function among persons with and without peripheral artery
disease.
In unadjusted linear regression models (Table 2), lower
cognitive function levels were associated with microalbumin-
uria among persons with and without peripheral artery
disease (8.7 (95% confidence interval (CI): 13.9, 3.6)
and 6.6 (95% CI: 8.7, 4.4), respectively). After adjusting
for confounders in a base model (including age, race/
ethnicity, gender, education, smoking, diabetes, and hyper-
tension), the magnitude of the difference in cognitive
function associated with microalbuminuria among persons
with peripheral artery disease was attenuated slightly to 6.7
(95% CI: 9.9, 3.5). The association between micro-
Table 1 | Characteristicsa of NHANES 1999–2002 study participants 60 years of age and older, overall and by MA
Total No MA MA
N=2386 N=1938 N=448 P-value
Age, years 70.6 (0.272) 69.9 (0.270) 73.1 (0.456) o0.001
Ethnicity, %
White 90.1 90.5 88.9 0.100
African American 7.0 6.6 8.0
Mexican American 3.0 2.9 3.2
Gender, % male 43.5 41.4 49.4 o0.001
High school education, % 71.7 74.0 64.5 0.001
Alcohol use, % 61.9 62.6 59.1 0.253
Current smoking, % 12.2 12.0 12.6 0.741
Hypertension, % 65.7 62.4 76.0 o0.001
Diabetes, % 13.1 11.0 19.6 o0.001
% glycohemoglobin 5.7 5.7 6.0 o0.001
Systolic BP, mm Hg 138 (0.772) 135 (0.687) 146 (1.38) o0.001
Diastolic BP, mm Hg 69.0 (0.538) 69.1 (0.488) 68.3 (1.21) 0.488
Serum glucose,b mg per 100 ml 103 (0.861) 99.8 (0.869) 112 (2.26) o0.001
Body mass index, kg m2 28.23 (0.138) 28.3 (0.158) 28.1 (0.333) 0.625
C-reactive protein, mg per 100 ml 0.52 (0.027) 0.488 (0.024) 0.623 (0.042) 0.010
Ankle-brachial index 1.10 (0.004) 1.10 (0.004) 1.09 (0.006) 0.268
Peripheral artery disease,c % 10.4 9.90 12.4 0.109
DSS score 47.7 (0.670) 49.6 (0.752) 41.6 (0.923) o0.001
Serum creatinine, mg per 100 ml 0.96 (0.008) 0.938 (0.007) 1.02 (0.018) o0.001
ACR, mg g1 21.5 (0.772) 8.27 (0.184) 60.4 (1.96) o0.001
Estimated GFR 75.4 (0.644) 76.1 (0.591) 73.2 (1.44) 0.063
Estimated
GFRo60 ml min1 1.73 m2, %
18.9 17.2 23.7 0.004
ACR, urinary albumin-to-creatinine-ratio; BP, blood pressure; DSS, digit symbol substitution; GFR, glomerular filtration rate; MA, microalbuminuria (defined as ACR
17–250mg g1 in men and 25–350mg g1 in women).
aMean (s.e.) for continuous variables and percentages for categorical variables.
bNonfasting serum glucose.
cPeripheral artery disease defined as ankle-brachial index o0.90 in at least one leg.
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Figure 1 | Prevalence of microalbuminuria (MA) by peripheral
artery disease (PAD) status and tertile of cognitive function.
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albuminuria and cognitive function among persons without
peripheral artery disease virtually disappeared when adjusting
for these same confounders. The addition of various potential
confounders singly to the base model, including coronary
heart disease, congestive heart failure, myocardial infarction,
stroke, anemia, and C-reactive protein, resulted in similar
regression estimates and 95% CIs as the base model among
participants with peripheral artery disease (data not shown).
In the full model including all covariates, the regression
coefficient for the association between microalbuminuria and
cognitive function among persons with peripheral artery
disease was 5.4 (95% CI: 8.9, 2.0; Po0.01).
Microalbuminuria was significantly associated with tertile
of cognitive function score among persons with peripheral
artery disease (Table 3). Upon adjustment for age, race/
ethnicity, gender, education, smoking, diabetes, and hyper-
tension, subjects with microalbuminuria had 6.5 (95%
CI: 2.0, 20.5) and 3.5 (95% CI: 1.2, 10.3) times the odds of
low and middle (versus highest) tertile cognitive function
score, respectively. Among persons without peripheral artery
disease, these risk estimates were not statistically significant.
Estimated GFRo60 ml min1 1.73 m2 was not consi-
dered a potential confounder, because it is potentially in
the causal pathway of microalbuminuria and cognitive
function. Fully adjusted logistic regression models that were
additionally adjusted for estimated GFRo60 ml min1
1.73 m2 showed virtually no change in the estimation of
the odds ratios (not shown).
DISCUSSION
This analysis of a nationally representative sample of
elderly individuals found that microalbuminuria is strongly
Table 2 | Mean differences in digit symbol substitution (DSS) score associated with microalbuminuria, adjusted for various
potential confounders, by peripheral artery disease (PAD) status
Mean difference in DSS score (95% confidence intervals)
Model PAD No PAD
Unadjusted 8.7 (13.9, 3.6)** 6.6 (8.7, 4.4)***
Adjusted for age, race/ethnicity, and gender 6.6 (11.9, 1.2)* 3.5 (5.6, 1.4)**
Adjusted for age, race/ethnicity, gender, education, diabetes,
smoking, and hypertension (base model)
6.7 (9.9, 3.5)*** 1.8 (4.1, 0.6)
Adjusted for base model,a total cholesterol, and high-density
lipoproteins (HDLs)
6.6 (9.7, 3.4)*** 2.2 (4.6, 0.3)
Adjusted for base modela and coronary heart disease (CHD) 6.4 (9.7, 3.1)*** 1.7 (4.1, 0.7)
Adjusted for base modela and congestive heart failure (CHF) 6.4 (9.5, 3.4)*** 1.7 (4.1, 0.7)
Adjusted for base modela and myocardial infarction (MI) 6.5 (9.8, 3.3) *** 1.7 (4.1, 0.6)
Adjusted for base modela and stroke 6.0 (9.2, 2.8)** 1.6 (4.0, 0.8)
Adjusted for base modela and anemia 6.8 (10.1, 3.5)*** 2.0 (4.3, 0.4)
Adjusted for base modela and C-reactive protein (CRP) 6.8 (10.0, 3.5)*** 2.1 (4.5, 0.2)
Adjusted for base model,a total cholesterol, HDL, CHD, CHF,
MI, stroke, anemia, and CRP
5.4 (8.9, 2.0)** 1.7 (4.0, 0.7)
*Po0.05; **Po0.01; ***Po0.001.
aBase model adjusted for age, race/ethnicity, gender, education, current smoking, diabetes, and hypertension.
Table 3 | Odds ratios for tertiles of cognitive function associated with microalbuminuria by peripheral artery disease status
Odds ratios (95% confidence intervals)
Tertile of cognitive function
Model 1 (DSS score 0–32) 2 (DSS score 33–51) 3 (DSS score 52–117)
Peripheral artery disease
Unadjusted 5.7 (1.9, 17.3) 2.9 (1.0, 8.8) 1.0
Adjusted for age, race/ethnicity, and gender 4.9 (1.4, 17.3) 2.7 (0.9, 8.4) 1.0
Adjusted for age, race/ethnicity, gender, education
smoking, diabetes, and hypertension (base model)
8.0 (2.4, 27.1) 2.9 (1.1, 7.9) 1.0
Adjusted for base model,a total cholesterol, HDL,
CHD, CHF, MI, stroke, anemia, and CRP
6.5 (2.0, 20.5) 3.5 (1.2, 10.3) 1.0
No peripheral artery disease
Unadjusted 3.1 (2.1, 4.5) 1.4 (1.1, 1.8) 1.0
Adjusted for age, race/ethnicity, and gender 2.3 (1.4, 3.6) 1.1 (0.8, 1.5) 1.0
Adjusted for age, race/ethnicity, gender, education
smoking, diabetes, and hypertension (base model)
1.8 (1.0, 3.3) 0.9 (0.6, 1.3) 1.0
Adjusted for base model,a total cholesterol, HDL,
CHD, CHF, MI, stroke, anemia, and CRP
1.8 (1.0, 3.4) 0.9 (0.6, 1.4) 1.0
CHD, coronary heart disease; CHF, congestive heart failure; CRP, C-reactive protein; DSS, digit symbol substitution test; HDL, high-density lipoproteins; MI, myocardial
infarction.
aBase model adjusted for age, race/ethnicity, gender, education, current smoking, diabetes, and hypertension.
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associated with cognitive impairment. Furthermore, the
association of microalbuminuria and cognitive impairment is
dramatically strengthened by the presence of peripheral artery
disease. Among persons with peripheral artery disease,
individuals with microalbuminuria had a statistically signi-
ficant 5.4 point lower average cognitive function score
than those with normal albumin-to-creatinine ratio. Micro-
albuminuria was also associated with a significant six-fold
increased odds of having the lowest tertile of cognitive function
among participants with peripheral artery disease. Among
individuals without peripheral artery disease, the magnitude of
the association was smaller and not statistically significant.
There are strong associations between cognitive test
scores and risk of dementia. Even small differences in cogni-
tive function test scores have been shown to be significant
predictors of dementia.18 In our study, we found mean DSS
scores of 49.6 among persons without microalbuminuria and
41.6 among persons with microalbumunuria. These means
are both significantly higher than the mean (±s.d.) DSS
scores previously reported for persons with Alzheimer’s
disease (ranging from 16.6 (±11.7) to 32.8 (±11.3)
depending on severity of the disease).18–21
In the Cardiovascular Health Cognition Study population,
low-baseline DSS scores were shown to be strongly related to
risk of dementia. The incidence of dementia was 69/1000
person-years for persons with DSS scores of 0–31 and
6.7/1000 person-years for persons with DSS scores of X51.18
Researchers demonstrated that even slightly lower cognitive
function scores over a short time course were predictors of
dementia. In another study, the DSS score was shown to be
nearly 1 s.d. lower in those with depressed and Alzheimer’s
type dementia compared to nondepressed controls.19 The
unweighted mean DSS score in the current population overall
was 42.4 with a s.d. of 18.5.
To our knowledge, this report is the first to demonstrate
an association between microalbuminuria and cognitive
function. Microalbuminuria may reflect the earliest stages
of CKD, as albuminuria predicts incident CKD.22 Previous
studies of cognitive impairment and CKD have focused on
later stages of kidney disease. For example, in a recent
prospective analysis of the Health, Aging, and Body
Composition study,7 the authors found that CKD (defined
by an estimated GFRo60 ml min1 1.73 m2) was associated
with a greater risk of developing cognitive impairment. Speci-
fically, this study observed significant adjusted odds ratios of
2.86 (95% CI: 1.73, 4.75) and 1.31 (95% CI: 1.04, 1.65) for
the association of estimated GFRo45 and 45–59 ml min1
1.73 m2 (compared to GFRX60 ml min1 1.73 m2), res-
pectively, with cognitive impairment. Adjustment for several
potential confounders was explored in separate models and
did not significantly alter the risk estimate. Urine proteins,
however, were not collected for this study and thus could not
be considered in the analysis.
Furthermore, peripheral vascular disease was not men-
tioned in the analysis as either a potential confounder or an
effect modifier. Our finding of a strengthened association of
microalbuminuria and cognitive impairment among persons
with peripheral artery disease may reflect greater underlying
early, unmeasured coronary and cerebrovascular disease in
this older population. It is possible that in this group of
persons with peripheral artery disease, there is unmeasured
confounding from asymptomatic atherosclerosis that resulted
in stronger associations between microalbuminuria and
cognitive impairment. Previous studies have demonstrated
an independent association of peripheral artery disease with
cognitive impairment,20,21 and peripheral artery disease
with renal insufficiency.23
Alternatively, microalbuminuria may be indicative of
generalized endothelial dysfunction and vascular ‘leakiness,’
a theory referred to as the Steno hypothesis.24–26 Endothelial
dysfunction has been suggested to underlie other diverse
processes including hypertension, atherosclerosis, retinal
abnormalities, peripheral artery disease, vascular dementia,
and Alzheimer’s disease.24,27–29 Endothelial damage is seen
widely in the brain of patients with advanced Alzheimer’s
disease as evidenced in autopsy studies.30–32 In a study of
patients with early stages of Alzheimer’s disease, research has
shown significant increases in the levels of markers of early
endothelial dysfunction (such as thrombomodulin and soluble
E-selectin).28 The only other study to report a significant
association between microalbuminuria and cognitive function
is by de Luis et al.,33 whose primary aim was to examine
homocysteine and cognitive deterioration in type II diabetics.
This study reported only univariate correlation results.
Although not directly tested, it is possible that endothelial
dysfunction could lead to cognitive impairment through a
series of pathophysiological steps including oxidative stress,
anemia leading to decreased oxygen delivery, and the build-
up of uremic toxins.34,35 Structural changes could develop
in the intima and media of blood vessels, subsequently
leading to ischemia in regions of the brain such as the deep
white matter. Our findings are consistent with these mecha-
nisms, because the relationship between microalbuminuria
and cognitive function is strengthened by the presence of
peripheral artery disease. Both microalbuminuria and
peripheral artery disease are likely indicators of the same
disease process, although at different stages. Peripheral artery
disease is likely a measure of more advanced endothelial
dysfunction than microalbuminuria alone.
The current study has several strengths. It uses data from a
large, nationally representative sample of the US population
X60 years of age to provide evidence of strong, consistent, and
significant associations between microalbuminuria and cogni-
tive function; considers a multitude of potential confounders;
and uses a strict protocol for the collection of data, especially
cognitive function, including quality control measures.
Certain limitations of the study should be noted. Only a
single measure of urine albumin and creatinine was collected
as part of the National Health and Nutrition Examination
Survey (NHANES) study. Measurements of urine albumin
and creatinine exhibit a high degree of intraindividual
variability and thus require repeat measures to ideally assess
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kidney function. On the other hand, a single positive
albuminuria result is sensitive to persistent albuminuria in
63.2% of all adults, and 72.7% in those with estimated GFR
below 90 ml min1 1.73 m2.36 Most of the participants in
this analysis fall into the range of mildly impaired kidney
function. In order for our results to be upwardly biased by
the use of a single measure, albuminuria would have to be less
likely to persist in those with cognitive impairment, which is
an unlikely scenario.
These results may not be generalizable beyond this
elderly population. Microalbuminuria and cognitive impair-
ment are risk factors for total mortality; therefore, measures
of association reported here may be underestimates due to
the competing risk of death. Cross-sectional analyses prevent
us from determining the temporal nature of the observed
associations. If the association between microalbuminuria
and cognitive function is valid, then microalbuminuria may
be either a true risk factor warranting direct intervention or
a risk indicator that predicts future morbidity but itself
plays no causal role.
There are some important potential implications of our
study. Cognitive impairment is a common condition that is
growing in prevalence as the population of the United States
ages. It is associated with significant morbidity and mortality.
Among individuals with CKD, cognitive impairment may be
even more common, and microalbuminuria has the potential
to identify persons at an elevated risk of cognitive decline.
Identifying and treating persons with signs of endothelial
dysfunction and/or early kidney disease may be a means
by which mental acuity can be preserved and the onset of
dementia can be prevented in older adults. Prospective
studies are needed to assess the temporality of peripheral
artery disease, microalbuminuria, and cognitive impairment.
MATERIALS AND METHODS
Study population
The NHANES 1999–2002 survey was designed to assess the health
and nutritional status of persons aged 2 months and older in the US
population. Cognitive function was measured only among study
participants who were at least 60 years of age at the time of the study
(N¼ 3706). Details of the NHANES 1999–2002 study participants
and methods have been previously published.37 Briefly, the study
design used a stratified, multistage cluster sampling design to obtain
a representative sample of the US noninstitutionalized, civilian
population. Oversampling of the very young, those aged 60 years
and older, African Americans, and Mexican Americans was done to
improve the precision of estimates in these subgroups. We excluded
persons with missing information on urine albumin or creatinine
and persons of race/ethnicity other than non-Hispanic white, non-
Hispanic black, or Mexican American, leaving 2386 participants for
the current analysis.
Measurement of cognitive function
Cognitive function was assessed by the Wechsler Adult Intelligence
Scale (WAIS) digit symbol substitution (DSS) test, which requires
the correct-timed coding of a series of symbols and emphasizes the
ability to pair symbols with their correct digits as well as the ability
to remember pairs. The DSS score is a measure of executive function
(such as self-regulation, prioritization of work, awareness of time,
abstract reasoning, logical analysis, hypothesis testing, and cognitive
flexibility). For this coding exercise, participants are asked to use
the key provided on the exercise form to pair and copy symbols
with their corresponding number. The score is calculated from
the number of correct symbols that are drawn in a 2-min period
with higher scores indicating better cognitive function (scores
ranged from 0 to 117). The DSS test is generally thought to be a
more sensitive measure of dementia than the widely used Mini-
Mental Status Exam.37 For quality control purposes, 10% of
the test forms were scored again by an independent second scorer.
The scores were compared and when necessary reconciled and
adjusted. The test–retest reliability over 2–5 weeks has been
previously reported to be 0.82 in persons aged 45–54 years.38 The
test is sensitive to language deficits and early mental decline in
elderly individuals.39 The DSS score is nearly 1 s.d. lower in those
with Alzheimer’s disease compared to non-Alzheimer’s controls.19
Measurement of microalbuminuria
Random, untimed urine specimens were collected from the
study participants using clean-catch techniques. Vials were stored
at 20 1C until they were shipped to the University of Minnesota
for testing. Urinary albumin concentration was measured by
solid-phase fluorescent immunoassay40 using a Fluorometer,
Sequoia-Turner Digital Model 450 (Turner Corporation, Mountain
View, CA, USA). Measurements were not performed on specimens
with hematuria. Urinary creatinine concentration was measured by
the modified kinetic method of Jaffe,41 using a Beckman Synchron
CX3 Clinical analyzer (Beckman Instruments Inc., Brea, CA, USA).
Microalbuminuria was defined as an albumin-to-creatinine ratio of
17–250 mg g1 in men and 25–350 mg g1 in women.42
Covariates
Several covariates were examined in the analyses. Demographic
variables included age, gender, race/ethnicity, and education.
Behavioral variables included current cigarette smoking (compared
to ever/never smoking). Health status indicators included systolic
and diastolic blood pressures, body mass index, and C-reactive
protein. Comorbid conditions included hypertension (blood
pressure 4140/90 mm Hg or taking hypertension medications),
anemia (hemoglobin o13.5 in men and o12 in women), and
peripheral artery disease, as well as self-reported diabetes, coronary
heart disease, congestive heart failure, myocardial infarction, and
stroke. Supine systolic blood pressure was measured on the right
arm (brachial artery) and on both ankles (posterior tibial arteries)
using a Parks Mini-Lab IV Doppler device. The left arm was used if
the participant had a condition that interfered with blood pressure
reading in the right arm. Systolic blood pressure was measured once
at each site for participants aged 60 years or more. Ankle-brachial
index was used to assess peripheral artery disease status. Measure-
ments for left and right ankle-brachial index were obtained by
dividing the mean ankle systolic blood pressure on each side by the
mean brachial systolic blood pressure. Peripheral artery disease was
defined as an ankle-brachial index less than 0.90 in at least one leg.43
Statistical methods
To account for the complex sampling design and weighting in
NHANES 1999–2002 and to obtain appropriate s.e. for all estimates,
all statistical analyses were conducted using survey weights in Stata,
version 8.0 (Stata Corporation, College Station, TX, USA). Means
(and s.e. for continuous variables and percentage of prevalence
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for categorical variables were calculated by microalbuminuria status.
To examine the association between kidney disease and cognitive
function, linear regression models were constructed with DSS
score as the dependent variable and microalbuminuria used as
the independent variable. Several covariates were included in the
multivariate models including age, race/ethnicity, gender, education,
smoking, diabetes, and hypertension. Models were additionally
adjusted for self-reported history of coronary heart disease,
congestive heart failure, myocardial infarction, stroke, anemia, and
C-reactive protein. Because comorbid conditions may be effect
modifiers, multiplicative interaction terms of microalbuminuria
with diabetes, hypertension, and peripheral artery disease status
were evaluated using linear regression models. A significant
interaction was evident between microalbuminuria with peripheral
artery disease (P¼ 0.011); therefore, all regression estimates are
presented by peripheral artery disease status. Interaction terms of
microalbuminuria with diabetes or hypertension were not signi-
ficant. Multinomial logistic regression models were constructed to
examine the association between microalbuminuria and tertile of
DSS score with and without adjustment for various covariates.
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